Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TNT Plus with Neoadjuvant Radiotherapy for Rectal Cancer
NCT06035133Phase 2Not yet recruiting
- Sponsor
- Tangdu Hospital
- Start
- Nov 2023
- Primary completion
- Nov 2024
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of KL-140, bevacizumab in rectal cancer, sponsored by Tangdu Hospital. Planned start Nov 2023; status: not yet recruiting.
02
Drugs
KL-140bevacizumab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT06035133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06035133.